Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GUSB | P08236 | 4/20 | 0.41 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.41 |
| ▸ | HAT1 | O14929 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 2/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708329 | 0.86 | PKM (0.40) | GUSBNHERF1HAT1EP300NR4A2 | |
| SCHEMBL14591887 | 0.83 | HAT1 (0.41) | RAB9AGUSBNHERF1HAT1EP300 | |
| SCHEMBL72972 | 0.83 | NHERF1 (0.54) | NHERF1HAT1EP300 | |
| SCHEMBL73753 | 0.80 | NHERF1 (0.51) | NHERF1HAT1EP300 | |
| SCHEMBL5066540 | 0.73 | GPR84 (0.65) | RAB9AMPOGPR84PCSK9 | |
| SCHEMBL14626738 | 0.72 | PCSK9 (0.41) | RAB9AGUSBNHERF1MPOHDAC3 | |
| SCHEMBL14591876 | 0.72 | PCSK9 (0.39) | RAB9AGUSBNHERF1HAT1EP300 | |
| SCHEMBL71893 | 0.72 | HDAC3 (0.48) | RAB9AHDAC3HDAC1 | |
| SCHEMBL72182 | 0.72 | MAOB (0.53) | RAB9A | |
| SCHEMBL71040 | 0.70 | ITGB1 (0.57) | HDAC1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | DAIICHI PHARMACEUTICAL CO.,LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1698611-A1 | PROCESS FOR PRODUCING PHENYLACETIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149606-A1 | Process for producing phenylacetic acid derivative | UGT1A4, VPS4B, CYP3A4 | RAB9A 3214/4885GUSB 506/4885NHERF1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.